Trial · NCT05790915
Impact of Interventions on Admission SOFA Score on Clinical Outcomes of Critically Ill Patients
NCT05790915, Completed, Hospital Sao Domingos
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of Interventions on Admission SOFA Score on Clinical Outcomes of Critically Ill Patients. Trials, record NCT05790915. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05790915
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of Interventions on Admission SOFA Score on Clinical Outcomes of Critically Ill Patients
- NCT number
- NCT05790915
- Status
- Completed
- Enrollment
- 849 participants, actual
- Lead sponsor
- Hospital Sao Domingos
- Conditions
- Critically Ill Patients
- Interventions
- Standardized interventions
- First posted
- 2023-03-30
- Last updated
- 2024-05-21
Source ClinicalTrials.gov
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Impact of standardized interventions in respiratory dysfunction on 48-hour delta SOFA with evaluation of the effectiveness of the interventions performed. | 48 hours | Lung protective ventilation: Tidal volume = 6 ml/kg; Plateau pressure \< 28 mmHg; driving pressue \< 16 cm H2O; Mechanical power \< 16 Joules/min; Prevention of self-inflicted lung injury (P-SILI): ROX index \> 4.8 and HACOR \< 5. The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with respiratory dysfunction and effective intervention / Number of patients with respiratory dysfunction X 100 |
| Primary | Impact of standardized interventions in hemodinamic dysfunction on 48-hour delta SOFA | 48 hour | SOSD (salvage, optimization, stabilization and de-escalation ) protocol; mean arterial pressoric taget of at least 65 mm Hg, Lactate serum level \< 19 mg/dL. The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with hemodinamic dysfunction and effective intervention / Number of patients with hemodinamica dysfunction X 100 |
| Primary | Impact of standardized interventions in neurologic dysfunction on 48-hour delta SOFA | 48 hour | Image: cranial CT; Electroencephalografic monitoring and RASS Score between -1 and +1 The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with neurologic dysfunction and effective intervention / Number of patients with neurologic dysfunction X 100 |
| Primary | Impact of standardized interventions in hematologic dysfunction on 48-hour delta SOFA | 48 hour | Basic disease approach; avoid drugs that interfere with coagulation; Platelet transfusion in case of hemohhage; DDAVP when indicated. The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with hematologic dysfunction and effective intervention / Number of patients with hematologic dysfunction X 100 |
| Primary | Impact of standardized interventions iin renal dysfunction on 48-hour delta SOFA | 48 hour | Avoid nephotoxic drugs; Mantain mean arterial blood pressure \> 65 mmHg The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with renal dysfunction and effective intervention / Number of patients with renal dysfunction X 100 |
| Primary | Impact of standardized interventions in hepatic dysfunction on 48-hour delta SOFA | 48 hour | Avoid hepatotoxic drugs;basic disease approach The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with hepatic dysfunction and effective intervention / Number of patients with hepatic dysfunction X 100 |
| Secondary | Impact of standardized interventions in respiratory dysfunction on ICU length of stay | 28 days | Lung protective ventilation: Tidal volume 6 ml/kg; Pateau pressure \< 28 mmHg; driving pressue \< 16 cm H2O; Mechanical power \< 16 Joules/min; Prevention of self-inflicted lung injury (P-SILI): ROX index \> 4.8 and HACOR \< 5. The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with respiratory dysfunction and effective intervention / Number of patients with respiratory dysfunction X 100 |
| Secondary | Impact of standardized interventions in hemodinamic dysfuction on ICU length of stay | 28 days | SOSD (salvage, optimization, stabilixation and de-escalation ) protocol; mean arterial pressoric taget of at least 65 mm Hg, Lactate serum level \< 19 mg/dL. The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with hemodinamic dysfunction and effective intervention / Number of patients with hemodinamic dysfunction X 100 |
| Secondary | Impact of standardized interventions in neurologic dysfunction on ICU length of stay | 28 days | Image: cranial CT; Electroencephalografic monitoring and RASS Score between -1 and +1 The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with neurologic dysfunction and effective intervention / Number of patients with neurologic dysfunction X 100 |
| Secondary | Impact of standardized interventions in hematologic dysfunction on ICU length of stay | 28 days | Basic disease approach; avoid drugs that interfere with coagulation; Platelet transfusion in case of hemohhage; DDAVP when indicated. The effectiveness of the interventions on organic disfunction will be evaluated through the formula: Number of patients with hematologic dysfunction and effective intervention / Number of patients with hematologic dysfunction X 100 |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05790915
GET https://conductscience.org/api/trials/v1/NCT05790915/registered?page=2